Focused On-demand Library for DDB1- and CUL4-associated factor 8

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q5TAQ9

UPID:

DCAF8_HUMAN

Alternative names:

WD repeat-containing protein 42A

Alternative UPACC:

Q5TAQ9; D3DVE6; Q12839; Q4QQI6; Q53F14; Q66K50; Q68CS7; Q96E00

Background:

DDB1- and CUL4-associated factor 8, also known as WD repeat-containing protein 42A, plays a crucial role in cellular processes as a substrate receptor for the CUL4-DDB1 E3 ubiquitin-protein ligase complex. This protein's involvement in the ubiquitination pathway underscores its importance in cellular homeostasis and protein degradation.

Therapeutic significance:

Linked to Giant axonal neuropathy 2, an autosomal dominant disorder, DDB1- and CUL4-associated factor 8's mutation highlights its critical role in neural health. Understanding its function could pave the way for innovative treatments for peripheral neuropathies and potentially cardiomyopathy.